Evidence map›Paper›PMID 24903939›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2014

Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253.

C H Shiboski, H Chen, M A Ghannoum, L Komarow, S Evans, P K Mukherjee, N Isham, D Katzenstein, A Asmelash, A E Omozoarhe and 5 more

Abstract readEvaluation Study
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Virulence ofJournal of fungi (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Anticandidal Activities byFrontiers in oral health · 2021
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

C H ShiboskiDepartment of Orofacial Sciences, School of Dentistry, University of California San Francisco, San Francisco, California, USA.
H ChenCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA.
M A GhannoumCenter for Medical Mycology, Department of Dermatology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio, USA.
L KomarowCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA.
S EvansCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA.
P K MukherjeeCenter for Medical Mycology, Department of Dermatology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio, USA.
N IshamCenter for Medical Mycology, Department of Dermatology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio, USA.
D KatzensteinStatistical Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts, USA.
A AsmelashStanford University Medical Center, Stanford, California, USA.
A E OmozoarheScottish Livingstone Hospital, Molepole, Botswana.
S Gengiah<label>**</label>Princess Marina Hospital, Gaborone, Botswana.
R AllenCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
S TripathyAIDS Clinical Trial Group Operations Center, Silver Spring, Maryland, USA.
S SwindellsMolecular Virology Clinic National AIDS Research Institute, Maharashtra Industrial Development Corporation, Bhosari, India.
AIDS Clinical Trials Group Network and Oral HIV/AIDS Research Alliance
Cancer Research And Biostatistics · USCase Western Reserve University · USCentre for the AIDS Programme of Research in South Africa · ZAStanford University · USAIDS Clinical Trials Group · USNational AIDS Research Institute · INUniversity of California, San Francisco · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
THE IMPACTA PERU CLINICAL TRIALS UNITUM1AI069438 · NIAID · ASOCIACION CIVIL IMPACTA SALUD Y EDUCACN · PI Alberto La Rosa, Jorge Luis Sanchez · 2012 to 2026
$43.2M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
NIAID NIH HHS 1U01 AI069423-01NIAID NIH HHS 1U01 AI069436-01NIAID NIH HHS 1U01 AI069438-01NIAID NIH HHS 1U01AI069453-01NIAID NIH HHS 1U01 AI069456-01NIAID NIH HHS 1U01 AI069463-01NIAID NIH HHS 1U01 AI069465-01NIAID NIH HHS 1U01 AI069469-01NIAID NIH HHS 1U01 AI069476-01NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI069417NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069436NIAID NIH HHS U01 AI069438NIAID NIH HHS U01 AI069453NIAID NIH HHS U01 AI069456NIAID NIH HHS U01 AI069463NIAID NIH HHS U01 AI069465NIAID NIH HHS U01 AI069469NIAID NIH HHS U01 AI069476NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1AI068636NIAID NIH HHS UM1 AI069417NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069438NIAID NIH HHS UM1 AI069456NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1AI68634PHS HHS 1U01 AL069432-01
6 · The paper itself

Abstract

objectiveTo evaluate the association between oral candidiasis and tuberculosis (TB) in human immunodeficiency virus (HIV) infected individuals in sub-Saharan Africa, and to investigate oral candidiasis as a potential tool for TB case finding.

methodsProtocol A5253 was a cross-sectional study designed to improve the diagnosis of pulmonary TB in HIV-infected adults in high TB prevalence countries. Participants received an oral examination to detect oral candidiasis. We estimated the association between TB disease and oral candidiasis using logistic regression, and sensitivity, specificity and predictive values.

resultsOf 454 participants with TB culture results enrolled in African sites, the median age was 33 years, 71% were female and the median CD4 count was 257 cells/mm(3). Fifty-four (12%) had TB disease; the prevalence of oral candidiasis was significantly higher among TB cases (35%) than among non-TB cases (16%, P < 0.001). The odds of having TB was 2.4 times higher among those with oral candidiasis when controlling for CD4 count and antifungals (95%CI 1.2-4.7, P = 0.01). The sensitivity of oral candidiasis as a predictor of TB was 35% (95%CI 22-48) and the specificity 85% (95%CI 81-88).

conclusionWe found a strong association between oral candidiasis and TB disease, independent of CD4 count, suggesting that in resource-limited settings, oral candidiasis may provide clinical evidence for increased risk of TB and contribute to TB case finding.

Indexed as

CoinfectionAdolescentAdultAfrica South of the SaharaAgedCandidiasis, OralCD4 Lymphocyte CountChi-Square DistributionCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMiddle AgedOdds Ratio

Identifiers

PMID24903939
PMCPMC4157598
OpenAlexW2070554458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.